Information for clinicians

IRON-PH is a randomized, double-blind, placebo-controlled, multicentre trial, assessing the impact of ferric carboxymaltose (FCM) on exercise capacity and functional status in pulmonary hypertension (PH).

The primary objective of the study is to determine the efficacy of FCM in improving exercise capacity relatively to matching placebo in patient with PH that suffer from iron deficiency. This objective will be assessed by measuring the change in 6MWD from baseline to 24 week follow-up. Secondary objectives are related to quality of life and cost-effectiveness.

The study aims to include 306 patients that will be recruited in approximately 7 hospitals in Belgium. 

For more information, refer to:
Protocol synopsis
Patient materials
Recruitment